ischemic heart disease
Conditions
Interventions
Patients will be given Aspirin 100mg + cilostazol 200mg orally twice daily. Both drugs will be administered to patients starting seven days or more prior to PCI.
Patients will be given Aspirin 100mg o
Sponsors
Department of Cardiology, Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with stable angina (2) Patients who will undergo PCI (Only those who use bare-metal stents)
Exclusion criteria
Exclusion criteria: (1)Patients with unstable angina (2)Patients who use drug-eluting stents (DES) (3)Patients with a medical history of acute myocardial infarction within three months (4)Patients whose levels of CK and CK-MB,troponin-I are above upper limits of normal at the time of consent acquisition (5)Patients taking an anticoagulant (warfarin) (6)Patients who have a medical history of hypersensitivity to cilostazol, aspirin, and/or clopidogrel (7)Patients with thrombocytopenia (8)Patients with hepatic dysfunction (AST (GOT) or ALT(GPT) > 100 IU/L within three months) (9)Patients with renal dysfunction (serum creatinine >2.0mg/dl within three months) (10)Patients with congestive heart failure (11)Patients who are pregnant (12)Patients with bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Frequency of increase of troponin-I above the upper limit of normal 2.Frequency of increase of CK >2 times above the upper limit of normal 3.Frequency of increase of CK-MB>2 times above the upper limit of normal 4.Average value of cardiac enzymes (CK/CK-MB/troponin-I) 5.Average rate of change of cardiac enzymes (CK/CK-MB/troponin-I) | — |
Countries
Japan
Contacts
Public ContactHideki Ishii
Nagoya University Graduate School of Medicine Department of Cardiology
Outcome results
None listed